{"id":7164,"date":"2019-12-31T16:14:48","date_gmt":"2019-12-31T10:44:48","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7164"},"modified":"2022-08-08T14:48:29","modified_gmt":"2022-08-08T09:18:29","slug":"dupilumab-therapy-for-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/dupilumab-therapy-for-atopic-dermatitis","title":{"rendered":"Atopic dermatitis market and a Dupilumab dominance"},"content":{"rendered":"\n

Dupilumab<\/strong>, a monoclonal antibody, is administered in the form of injection for the treatment of Atopic dermatitis<\/strong> <\/a>(Eczema<\/a>) in adults and children of age 12 and old. The injection works by hampering the substance in the body, which produces allergic reactions. Dupilumab is a receptor-antagonist and binds to the alpha subunit of the interleukin-4 receptor (IL-4R\u03b1). The blockade of IL-4R\u03b1, signalling of both the interleukin 4 and interleukin 13 pathways.\u00a0<\/p>\n\n\n\n

The injection is sold under the brand name Dupixent, and <\/strong>the drug is also given in combination with other medications to prevent wheezing, shortness of breath, coughing, and chest tightness due to certain types of asthma. Moreover, the injection is also administered to treat chronic rhinosinusitis with nasal polyposis in adults. <\/p>\n\n\n\n

Dupilumab<\/strong> is the only therapy present in the Atopic dermatitis market<\/a> that targets the IL-4\/IL-13 pathway, a key driver of allergies and inflammation type 2.\u00a0<\/p>\n\n\n\n

There are companies developing therapies to advance Atopic dermatitis market. Companies like Galderma Pharma, LEO Pharma, Roviant Sciences, and many others are developing drugs to fuel the Atopic dermatitis market. However, DelveInsight\u2019s analysts estimate that Dupilumab is likely to rule in the Atopic dermatitis market. <\/p>\n\n\n\n

For any other drug candidate to receive investigational therapy, the drug should be able to prove the drug in question, i.e., Dupilumab <\/strong>inferior. The novel drug should be able to have an improved dosing and a convenient administration method. <\/p>\n\n\n\n

Moreover, the new drug should be able to score higher points in the Eczema Area and Severity Index (EASI) or Investigator\u2019s Global Assessment (IGA) primary endpoint scoring systems. <\/p>\n\n\n\n

However, Atopic dermatitis upcoming therapies hold the potential to supersede the existing treatments and occupy a significant share of the market.<\/p>\n\n\n

<\/p>","protected":false},"excerpt":{"rendered":"

Dupilumab, a monoclonal antibody, is administered in the form of injection for the treatment of Atopic dermatitis (Eczema) in adults and children of age 12 and old. The injection works by hampering the substance in the body, which produces allergic reactions. Dupilumab is a receptor-antagonist and binds to the alpha subunit of the interleukin-4 receptor […]<\/p>\n","protected":false},"author":1,"featured_media":7165,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[7465,7478,7467,17926,17925,7476,7477],"industry":[17225],"therapeutic_areas":[17237],"class_list":["post-7164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-allergy-market","tag-atopic-dermatitis","tag-atopic-dermatitis-market","tag-atopic-dermatitis-upcoming-therapies","tag-dupilumab","tag-dupilumab-drug-insight","tag-dupilumab-therapy","industry-pharmaceutical","therapeutic_areas-dermatology"],"acf":[],"yoast_head":"\nAtopic dermatitis market | Dupilumab dominance in AD market<\/title>\n<meta name=\"description\" content=\"Dupilumab is the only therapy present in the Atopic dermatitis market that targets the IL-4\/IL-13 pathway, a key driver of allergies and inflammation type..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/dupilumab-therapy-for-atopic-dermatitis\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atopic dermatitis market | Dupilumab dominance in AD market\" \/>\n<meta property=\"og:description\" content=\"Dupilumab is the only therapy present in the Atopic dermatitis market that targets the IL-4\/IL-13 pathway, a key driver of allergies and inflammation type..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/dupilumab-therapy-for-atopic-dermatitis\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-31T10:44:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-08T09:18:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/31152155\/atopic-dermetitis-31.12.2019.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Atopic dermatitis market | Dupilumab dominance in AD market","description":"Dupilumab is the only therapy present in the Atopic dermatitis market that targets the IL-4\/IL-13 pathway, a key driver of allergies and inflammation type..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/dupilumab-therapy-for-atopic-dermatitis","og_locale":"en_US","og_type":"article","og_title":"Atopic dermatitis market | Dupilumab dominance in AD market","og_description":"Dupilumab is the only therapy present in the Atopic dermatitis market that targets the IL-4\/IL-13 pathway, a key driver of allergies and inflammation type..","og_url":"https:\/\/www.delveinsight.com\/blog\/dupilumab-therapy-for-atopic-dermatitis","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-12-31T10:44:48+00:00","article_modified_time":"2022-08-08T09:18:29+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/31152155\/atopic-dermetitis-31.12.2019.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/dupilumab-therapy-for-atopic-dermatitis","url":"https:\/\/www.delveinsight.com\/blog\/dupilumab-therapy-for-atopic-dermatitis","name":"Atopic dermatitis market | Dupilumab dominance in AD market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/dupilumab-therapy-for-atopic-dermatitis#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/dupilumab-therapy-for-atopic-dermatitis#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/31152155\/atopic-dermetitis-31.12.2019.jpg","datePublished":"2019-12-31T10:44:48+00:00","dateModified":"2022-08-08T09:18:29+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Dupilumab is the only therapy present in the Atopic dermatitis market that targets the IL-4\/IL-13 pathway, a key driver of allergies and inflammation type..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/dupilumab-therapy-for-atopic-dermatitis"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/dupilumab-therapy-for-atopic-dermatitis#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/31152155\/atopic-dermetitis-31.12.2019.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/31152155\/atopic-dermetitis-31.12.2019.jpg","width":772,"height":482,"caption":"Atopic dermatitis market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/31152155\/atopic-dermetitis-31.12.2019-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">allergy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Atopic dermatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Atopic dermatitis Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Atopic Dermatitis Upcoming Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dupilumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dupilumab drug Insight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dupilumab therapy<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">allergy market<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis Market<\/span>","<span class=\"advgb-post-tax-term\">Atopic Dermatitis Upcoming Therapies<\/span>","<span class=\"advgb-post-tax-term\">Dupilumab<\/span>","<span class=\"advgb-post-tax-term\">Dupilumab drug Insight<\/span>","<span class=\"advgb-post-tax-term\">Dupilumab therapy<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Dec 31, 2019","modified":"Updated on Aug 8, 2022"},"absolute_dates_time":{"created":"Posted on Dec 31, 2019 4:14 pm","modified":"Updated on Aug 8, 2022 2:48 pm"},"featured_img_caption":"Atopic dermatitis market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7164"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7164\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7165"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7164"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7164"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}